GlassScriptPhysician profile
Hassan Alhalabi
NPI 1376796656
$1,499.80
in general payments reported to CMS, 2019-2025
23 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $14.35 · 2021: $38.44 · 2022: $188 · 2023: $287 · 2024: $234 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127 · Education: $0.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.54 |
| Education | $0.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $215.37 | 2022-2025 | Farxiga |
| Fresenius USA Marketing, INC. | $174.49 | 2022-2025 | Nxstage System One, Velphoro, Velphoro |
| Travere Therapeutics, INC. | $138.22 | 2024-2025 | Filspari |
| Amgen INC. | $132.66 | 2024-2025 | Tavneos, Krystexxa |
| Aurinia Pharma U.S., INC. | $106.85 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $87.21 | 2019-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $76.51 | 2022-2024 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $69.49 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.26 | 2025 | Jardiance |
| Horizon Therapeutics Plc | $54.87 | 2022-2023 | Krystexxa |
| Ardelyx, INC. | $44.68 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $44.38 | 2019-2022 | |
| Scpharmaceuticals INC. | $38.49 | 2025 | |
| Janssen Pharmaceuticals, INC | $38.25 | 2019-2023 | Xarelto |
| Allergan, INC. | $37.42 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.09 | 2022-2023 | Gattex |
| Novartis Pharmaceuticals Corporation | $33.36 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $29.48 | 2025 | Acthar |
| Inspire Medical Systems, INC. | $21.05 | 2025 | Inspire |
| Calliditas Therapeutics US INC. | $18.85 | 2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $16.74 | 2023 | |
| Vantive US Healthcare LLC | $16.24 | 2025 | Renal - Pd |
| Opko Pharmaceuticals, LLC | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Alhalabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.